NRC FORM 374
(10-59)

U.S. NUCLEAR REGULATORY COMMISSION

MATERIALS LICENSE

Amendment No. 4

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 39, 40 and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee	
1. Roanoke Memorial Hospital Nuclear Pharmacy Services	In accordance with letter dated November 19, 1992 3. License number 45-01291-04MD is amended in its entirety to read as follows:
2. Belleview at Jefferson Street Roanoke, Virginia 24033	4. Expiration date April 30, 1993
	5. Docket or Reference No 030-20060

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license
A. Molybdenum 99	A. Any molybdenum 99/technetium 99m generator manufactured, labeled, packaged and distributed in accordance with a specific license issued pursuant to 10 CFR 32.73 or a specific license issued to the manufacturer by an Agreement State pursuant to equivalent State regulations	A. 12 curies
B. Any byproduct material listed in paragraph 10 CFR 31.11(a)	B. Prepackaged in vitro diagnostic test kits	B. 5 millicuries total possession limit
C. Any byproduct materia authorized under 10 CFR 35.57(a) (effective 4/1/87) or 10 CFR 35.14(d)(4) (superseded)	C. Any sealed source listed in 10 CFR 35.14(d) (superseded) or 10 CFR 35.57(a) (effective 4/1/87) that has been manufactured, labeled, packaged and distributed in accordance with a specific license issued pursuant to 10 CFR 32.74 or a specific license issued to the manufacturer by an Agreement State pursuant to equivalent State regulations	C. As needed

ML20

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License number 45-01291-04MD

Docket or Reference number 030-20060

Amendment No. 4

6. Byproduct, source, and/or special nuclear material	7. Chemical and/or physical form	8. Maximum amount that licensee may possess at any one time under this license
D. Xenon 133	D. Unit dose containers of gas or gas in solution that is the subject of an active (i.e., not withdrawn or terminated) "New Drug Application" (NDA) approved by FDA or an active (i.e., not withdrawn, terminated, or on "clinical hold") "Notice of Claimed Investigational Exemption for a New Drug" (IND) that has been accepted by FDA	D. 3.0 curies total for all xenon authorized under License Nos. 45-01291-02 and 45-01291-04MD
E. Iodine 131	E. Any form listed in Groups I through V of Schedule A, 10 CFR 35.100 (superseded) or 10 CFR 35.100, 35.200, or 35.300 (effective 4/1/87)	E. 300 millicuries
F. Technetium 99m	F. Any form listed in Groups I and III of Schedule A, 10 CFR 35.100 (superseded) or 10 CFR 35.200 and 35.200 (effective 4/1/87)	F. 12 curies
G. Any byproduct material except iodine 131 and technetium 99m, listed in Group I of Schedule A, 10 CFR 35.100 (superseded) or 10 CFR 35.100 (effective 4/1/87).	G. Any form listed in Group I of Schedule A, 10 CFR 35.100 (superseded) or 10 CFR 35.100 (effective 4/1/87)	G. 50 millicuries total possession limit
H. Any byproduct material, except iodine 131 and technetium 99m, listed in Group II of Schedule A, 10 CFR 35.100 (superseded) or 10 CFR 35.200 (effective 4/1/87).	H. Any form listed in Group II of Schedule A, 10 CFR 35.100 (superseded) or 10 CFR 35.200 (effective 4/1/87)	H. 100 millicuries total possession limit
I. Any byproduct material except iodine 131, listed in Group IV of Schedule A, 10 CFR 35.100 (superseded) or 10 CFR 35.300 (effective 4/1/87)	I. Any form listed in Group IV of Schedule A, 10 CFR 35.100 (superseded) or 10 CFR 35.300 (effective 4/1/87)	I. 100 millicuries total possession limit

9. Authorized Use:

A. Production of technetium 99m pertechnetate.
B. Redistribution to specific licensees in accordance with statements representations and procedure contained in letter dated April 1, 1983.
C. Instrument calibration.
D. Distribution to authorized recipients.
E. Dispensing and/or distribution of prepared radiopharmaceuticals to authorized recipients.
F. Dispensing and/or distribution of prepared radiopharmaceuticals to authorized recipients. Use of technetium 99m pertechnetate for processing with reagent kits in preparing radiopharmaceuticals.
G through I. Dispensing and/or distribution of prepared radiopharmaceuticals to authorized recipients.

Pursuant to 10 CFR 32.72, the licensee is authorized to distribute the byproduct material described in Items 6 and 7 of this license to persons licensed pursuant to 10 CFR 35.14 and 35.100 (superseded) or 10 CFR 35.100, 35.200 and 35.300 (effective 4/1/87), or under equivalent licenses of Agreement States, for the Groups or Sections indicated below:

D. Gas or gas in saline may be distributed to persons licensed pursuant to 10 CFR 35.200 (effective 4/1/87).
E. through I. Any form listed in each group, Groups I, II, IV and V of Schedule A, 10 CFR 35.100 (superseded) or authorized by 10 CFR 35.100, 35.200 and 35.300 (effective 4/1/87), may be distributed to persons licensed pursuant to that group or section.

CONDITIONS

10. Licensed material shall be used only at Roanoke Memorial Hospitals, Nuclear Pharmacy Services, Belleview at Jefferson Streets, Roanoke, Virginia.

11. A. Licensed material shall be used by, or under the supervision of, Robert W. Beightol, Marshall A. Wakat, M.D., William F. Weller, M.D., or J. Bruce Hauser, M.D.

B. At least one individual named in Condition 11.A. shall be physically present at the authorized place of use whenever licensed material is being used, for the purpose authorized in Item 9 above.

12. The Radiation Safety Officer for this license is Joseph L. Surace, M.S.

13. A. Sealed sources specified in Item 7.C. shall be tested for leakage and/or contamination at intervals not to exceed 6 months or at such other intervals as specified by the certificate of registration referred to in 10 CFR 32.210.

B. Notwithstanding Paragraph A of this Condition, sealed sources designed to emit alpha particles shall be tested for leakage and/or contamination at intervals not to exceed 3 months.

C. In the absence of a certificate from a transferor indicating that a leak test has been made within six months prior to the transfer, a sealed source or detector cell received from another person shall not be put into use until tested.

D. Each sealed source fabricated by the licensee shall be inspected and tested for construction defects, leakage, and contamination prior to any use or transfer as a sealed source.

continued

CONDITIONS

13. E. Sealed sources need not be leak tested if:

(i) they contain only hydrogen-3; or

(ii) they contain only a radioactive gas; or

(iii) the half-life of the isotope is 30 days or less; or

(iv) they contain not more than 100 microcuries of beta and/or gamma emitting material or not more than 10 microcuries of alpha emitting material; or

(v) they are not designed to emit alpha particles, are in storage, and are not being used. However, when they are removed from storage for use or transferred to another person, and have not been tested within the required leak test interval, they shall be tested before use or transfer. No sealed source or detector cell shall be stored for a period of more than 10 years without being tested for leakage and/or contamination.

F. The leak test shall be capable of detecting the presence of 0.005 microcurie of radioactive material on the test sample. Records of leak test results shall be kept in units of microcuries and shall be maintained for inspection by the Commission. If the test reveals the presence of 0.005 microcurie or more of removable contamination, a report shall be filed with the U.S. Nuclear Regulatory Commission and the source shall be removed immediately from service and decontaminated, repaired, or disposed of in accordance with Commission regulations. The report shall be filed within 5 days of the date the leak test result is known with the U.S. Nuclear Regulatory Commission, Region II, ATTN: Chief, Nuclear Materials Licensing Section, 101 Marietta Street, Suite 2900, Atlanta, GA 30323. The report shall specify the source involved, the test results, and corrective action taken. Records of leak test results shall be kept in units of microcuries and shall be maintained for inspection by the Commission. Records may be disposed of following Commission inspection.

H. Tests for leakage and/or contamination shall be performed by the licensee or by other persons specifically licensed by the Commission or an Agreement State to Perform such services.

14. A. Radiopharmaceuticals dispensed and/or distributed for human use shall be either:

(i) Repackaged from prepared radiopharmaceuticals that are the subject of an FDA-approved "New Drug Application" (NDA) or for which FDA has accepted a "Notice of Claimed Investigational Exemption for a New Drug" (IND); or

(ii) Prepared from generators and reagent kits that are the subject of an FDA-approved NDA or for which FDA has accepted an IND.

continued

CONDITIONS

14. B. Prepared radiopharmaceuticals for which FDA has accepted an IND and radiopharmaceuticals prepared from generators or reagent kits for which FDA has accepted an IND shall be dispensed and/or distributed:

(i) In accordance with the directions provided by the sponsor of the IND; and

(ii) Only to physicians who have been accepted by the sponsor of the IND to participate in clinical evaluation of the drug.

C. The licensee shall inform in writing each physician who participates in an IND evaluation that the physician is responsible to the sponsor of the IND for use of the drug in accordance with protocols established by the sponsor and for reporting to the sponsor the clinical information obtained through use of the drug.

15. The licensee shall elute generators and process radioactive material with reagent kits in accordance with instructions furnished by the manufacturer on the label attached to or in the leaflet or brochure that accompanies the generator or reagent kit.

16. Reagent kits may be redistributed to persons licensed pursuant to 10 CFR 35.200 or under equivalent licenses of Agreement States or 10 CFR 35.14 and 35.100 (superseded).

17. The licensee is authorized to hold radioactive material with a physical half-life of less than 65 days for decay-in-storage before disposal in ordinary trash provided:

A. Radioactive waste to be disposed of in this manner shall be held for decay a minimum of 10 half-lives.

B. Before disposal as ordinary trash, byproduct material shall be surveyed at the container surface with the appropriate meter set on its most sensitive scale and with no interposed shielding to determine that its radioactivity cannot be distinguished from background. All radiation labels shall be removed or obliterated.

C. Generator columns shall be segregated so that they may be monitored separately to ensure decay to background levels prior to disposal.

D. A record of each disposal permitted under this License Condition shall be retained for three years. The record must include the date of disposal, the date on which the byproduct material was placed in storage, the radionuclides disposed, the survey instrument used, the background dose rate, the dose rate measured at the surface of each waste container, and the name of the individual who performed the disposal.

18. The licensee is authorized to transport licensed material only in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."

19. Any proposed changes in packaging, labeling, shielding, or instructions for use and storage shall be submitted for review to the Nuclear Materials Licensing Section, U.S. Nuclear Regulatory Commission, Region II, 101 Marietta Street, Suite 2900, Atlanta, GA 30323 and approval of the changes shall be received by the licensee prior to implementing the changes.

20. Sealed sources containing licensed material shall not be opened by the licensee.

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License number 45-01291-04MD

Docket or Reference number 030-20060

Amendment No. 4

continued

CONDITIONS

21. The licensee shall conduct a physical inventory every 6 months to account for all sources and/or devices received and possessed under the license. Records of inventories shall be maintained for 2 years from the date of each inventory, and shall include the quantities and kinds of byproduct material, manufacturer's name and model numbers, location of the sources and/or devices, and the date of the inventory.

22. The licensee shall conduct a bioassay program in accordance with the procedures set forth in Regulatory guide 8.20 "Applications of Bioassay for Iodine 125 and Iodine 131", September 1979.

23. The licensee shall maintain records of information important to safe and effective decommissioning at the location specified in Condition 10 in accordance with the provisions of 10 CFR 30.35(g) until this license is terminated by the Commission.

24. In addition to the possession limits in item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance.

25. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents including any enclosures, listed below. The Nuclear Regulatory Commission's regulations shall govern unless the statements, representations and procedures in the licensee's application and correspondence are more restrictive than the regulations.

A. Applications dated November 29, 1982 and March 14, 1988
B. Letters dated March 18, 1983 and April 1, 1983
C. Letter dated June 24, 1988
D. Letter dated June 18, 1992
E. **Letter dated November 19, 1992 (letter requesting approval for new radiopharmacy location)**
F. **Letter dated January 21, 1993 (letter with additional information concerning the fumehood and ventilation system)**
G. **Letter dated January 22, 1993 (letter with additional information concerning the use of 2 filters in fumehood)**

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

EARL G. WRIGHT

Date JAN 29 1993

By Earl G. Wright

Region II, Nuclear Material Licensing Section
101 Marietta Street, Suite 2900
Atlanta, GA 30323

Roanoke
Memorial
Hospitals

An Affiliate of **CARILION** *Health System*

January 22, 1993

Ms. Sandra Waldron
License Reviewer
Region II
Nuclear Regulatory Commission
101 Marietta Street, NW
Atlanta, GA 30323

RE: Response to request for additional amendment information

The following is in response to your request for additional information regarding our Radiopharmacy fume hood. As per our conversation on January 22, 1993 regarding whether or not a second charcoal filter will be placed in the existing fume hood exhaust line. A second charcoal filter will be inserted into this exhaust line, and routinely be used. Both the first and second filters will be monitored on a quarterly basis.

If any additional information is necessary, please contact me at your convenience. I appreciate your attention to our application request, and look forward to its successful implementation.

Respectfully submitted,

Joseph L. Surace
Radiation Safety Officer

bp

Roanoke
Memorial
Hospitals

An Affiliate of **CARILION** *Health System*

January 21, 1993

Ms. Sandra Waldron
License Reviewer
Region II
Nuclear Regulatory Commission
101 Marietta Street, NW
Atlanta, GA 30323

RE: Response to request for additional amendment information

The following is in response to your request for additional information on our ventilation system for our proposed Radiopharmacy site.

The proposed site is located on the 4th floor (Suite 420) of the West Wing of Roanoke Memorial Hospitals. The radioiodine fume hood would be directly vented from this 4th floor location at a minimum of 80 cubic feet per minute as follows. This air be vented directly to a closed duct system, which has a present air flow rate of 410 cfm at the face of a 6" x 20" air duct. Air would be vented laterally along this floor collecting air from other rooms along the hallway. The 410 cfm is measured at the end of this duct system, and would be considered the minimum flow rate.

As air flows along this lateral duct work, the actual air flow increases as it is turned vertically and vents directly out a ventilator located on the roof above the 15th floor. At the point where the air actually leaves the building site, the minimum air flow is in excess of 10,000 cfm at the point of exit.

I have attached a diagram which I hope helps describe the ventilation system as it presently exists.

Additionally, upon review it was observed in our previous submission of January 6, 1993, that the air flow per week was indicated as 2.85×10^{9} ml/wk. This in fact is an underestimate. This number should be revised to 2.28×10^{10} ml/wk, resulting in an average air concentration of 1.15×10^{-13} μCi/ml.

Roanoke Memorial Hospitals
Belleview at Jefferson Street Post Office Box 13367 Roanoke, Virginia 24033 Telephone 703-981-7000

Also, you expressed concern over the security of this roof area. This is a limited access roof area, restricted to maintenance personnel. No general public occupies this area, and relatively little time is incurred here by maintenance personnel.

I hope this information is sufficient, and remain available if you have any additional questions.

Respectfully submitted,

Joseph T. Surace
Radiation Safety Officer

bp

Radiological
Physics Services

*A Service of Roanoke Memorial Hospitals
provided through Health East, Inc.*

An Affiliate of **CARILION** *Health System*



ROANOKE MEMORIAL HOSP
RADIOPHARMACY RELOCATION
VENTILATION ROUTE - I-131

1/20/93

Radiological Physics Services
Post Office Box 13367 Roanoke, Virginia 24033 Telephone 703-981-7370

NRC FORM 216 (4 781)
NRCM 0240

U.S. NUCLEAR REGULATORY COMMISSION

DATE 1/12

TELEPHONE OR VERBAL CONVERSATION RECORD

TIME 10 00 AM 00 ☐ A.M. ☑ P.M.

☐ INCOMING CALL ☑ OUTGOING CALL ☐ VISIT

PERSON CALLING	OFFICE/ADDRESS	PHONE NUMBER	EXTENSION
Swalden			7379
PERSON CALLED	**OFFICE/ADDRESS**	**PHONE NUMBER**	**EXTENSION**
Joe Surace	Roanoke rgnl.	703-981-~~7600~~	

CONVERSATION

SUBJECT: Dic. Amend.

SUMMARY

~~The exhaust~~ The hood is an Atomic Prod. minihood. The config in letter of 1/6/93 is not what is currently in place, but for proposed move of pharmacy. Mr Surace said that during test that fume hood vents into ~~the~~ had other vents that flow into it - no recirculation - no blowers below location where hood vented. There is a mega blower/fan @ the roof which allows upto 20,000 cfm exhaust w/ a min of 10K cfm. Will perform wipe of exhaust baffles in ~1qtr. to see if any contamination. Will start using and filter in minihood. Receive 15 mCi stock solution every other week. Iodine is drawn from stock by opening lid & pouring into vial. When I asked about procedures in case of spill, he stated they had been previously submitted. He will send letter addressing these

REFERRED TO: ISSUED

☐ ADVISE ME OF ACTION TAKEN.

ACTION REQUESTED

INITIALS

DATE

ACTION TAKEN

INITIALS

DATE

Roanoke
Memorial
Hospitals

January 6, 1993

An Affiliate of **CARILION** *Health System*

Ms. Sandra Waldron
License Reviewer
Region III
Nuclear Regulatory Commission
101 Marietta Street, NW
Atlanta, GA 30323

RE: Response to request for additional amendment information

The following information is in response to your request of January 4, 1993 for additional information to our amendment request for relocation of our Radiopharmacy, dated November 19, 1992:

1. The radioiodine fume hood is vented directly from our 4th floor location at 80 cubic feet per minute to a sewage vent exhibiting an air flow of about 1000 cubic feet per minute and finally to a heat exchanger ventilator located on the 15th floor which runs constantly at greater than 10,000 cubic feet per minute. The minimum height of this ventilator above the roof is 2 feet to a maximum height of approximately 9 feet. Its location is on the highest roof level of the building, and is not routinely occupied by personnel. Photos enclosed are of the ventilator exhaust area, and the general ventilator environment.

2. No fresh air intakes are located within 17 feet of the current stack position.

3. The present radioiodine fume hood was purchased from Atomic Products, and is specifically designed for the needs of iodination procedures. It is constructed of 3/8 clear plexiglass, and provides a large internal working area to allow uninhibited manipulation of material within the unit. Circular access portals are used for gaining access to the radioiodine. A baffled air flow is used to assure even flow speed of air out of the hood, while a negative air flow speed can be adjusted to a maximum of 80 cubic feet per minute. The fume hood includes a 12" x 1" disposable charcoal filter that traps 90% of the radioiodine produced, and can accommodate two filters if needed. The filter and the exhaust fan blower are an intrical part of the radioiodine fume hood, and are located directly at the exit portal of the fume hood.

Regarding the affluent concentration to unrestricted areas, the following is submitted:

Average stock activity integrated over a two week period: 38 mCi
Trap efficiency: 90%
Air flow: 2.85×10^{3} ml per week

Roanoke Memorial Hospitals
Belleview at Jefferson Street Post Office Box 13367 Roanoke, Virginia 24033 Telephone 703-981-7000

Iodine volatilization: 0.01%
Maximum amount of time stock solution is open to the atmosphere: 70 minutes per week
Number of minutes per week: 10080

Average concentration (μCi/ml) = ([38 mCi/wk x .0001 x .1 x 1000 μCi/mCi]/2.854 x 10^{6} ml/wk) x 70 min/10080 min = 9.2 x 10^{-11} μCi/ml.

This is significantly less than the current standard in 10 CFR Part 20 of 2 x 10^{-10} μCi/ml for Iodine 131.

Regarding your question of the monitoring of the filter and the frequency of testing. The filter is removed and monitored on a quarterly basis. Our experience has shown that under routine iodine use that monitoring of the filter on a quarterly basis exhibits readings from 2 to 3 times above background, prevalent at the end of one year. The filter is changed on an annual basis unless quarterly monitoring indicates excessive radiation exposure. With the filter typically at a maximum of 2 to 3 times background, and this hood being located in a radiation area, these levels have not significantly affected the ambient radiation environment. Additionally personnel monitoring records and bioassays of the thyroid area on individuals indicate no levels of concern.

Regarding the minimum face velocity at the front of this hood, it is measured with a velometer (ALNOR Series 600P) on a quarterly frequency. Last indicated measurement (9-15-92) indicates a face velocity of 27 cubic feet per minute.

Finally with relocation of the Radiopharmacy, decontamination procedures in accordance with appropriate regulatory guide issued by the Nuclear Regulatory Commission will be conducted on existing areas and a close out survey provided for your records.

I appreciate the opportunity to provide answer to your questions, and feel free to contact me if additional questions or concerns arise.

Sincerely,

Joseph Louis Surace
Radiation Safety Officer

bp

Licensee stated guide referred to is Guidelines for decont of facilities & equipment prior to release for unrestricted use or termination of licenses for Byproduct, Source or SNM 8/87 SWaldron



Exhaust Ventilator, Environments

Roanoke Memorial Hosp 1/5/93



Exhaust Ventilator
Surface Grill
Roanoke Mem. Hosp 1/5/93

NRC FORM 318
(4 781)
NRCM 0240

U.S. NUCLEAR REGULATORY COMMISSION

DATE 1/4/93

TELEPHONE OR VERBAL CONVERSATION RECORD

TIME 1:15 ☐ A.M. ☐ P.M.

☐ INCOMING CALL ☒ OUTGOING CALL ☐ VISIT

PERSON CALLING	OFFICE/ADDRESS	PHONE NUMBER	EXTENSION
S Waldron	RII		

PERSON CALLED	OFFICE/ADDRESS	PHONE NUMBER	EXTENSION
Joe Surace	Roanoke Mem.		

CONVERSATION

SUBJECT: Amend. To move Radiopharmacy

SUMMARY

Discussed that add'l info needed on furnehood & exhaust systems ref approval relocation: Stack Ht., distance from fresh air intakes & vent, windows; location of filter & blower - method & freq of in place filter testing; min. face velocity - method & freq of checks.

Also need more detailed decontamination guidelines, max. fixed & removable contamin. bef. release.

Furnehood is being moved

Send copy of closeout

Calculations that released are w/in 10 CFR 20 Appd B limits.

REFERRED TO:

☐ ADVISE ME OF ACTION TAKEN.

ACTION REQUESTED

Will fax info 1/5/93

INITIALS

DATE

ACTION TAKEN

INITIALS

DATE

BETWEEN:

LICENSE FEE MANAGEMENT BRANCH, ARM
AND
REGIONAL LICENSING SECTIONS

(FOR LFMS USE)
INFORMATION FROM LTS

PROGRAM CODE: 02500
STATUS CODE: 0
FEE CATEGORY: 3C
EXP. DATE: 19930430
FEE COMMENTS: NOT 3N 4/25/88 CALL
DECOM FIN ASSUR REQD: N

LICENSE FEE TRANSMITTAL

A. REGION

1. APPLICATION ATTACHED
APPLICANT/LICENSEE: ROANOKE MEMORIAL HOSPITAL
RECEIVED DATE: 921207
DOCKET NO: 3020060
CONTROL NO.: 255065
LICENSE NO.: 45-01291-04MD
ACTION TYPE: AMENDMENT

2. FEE ATTACHED
AMOUNT: 490.00
CHECK NO.: 802960

3. COMMENTS

SIGNED Diane O'Hara
DATE 12/10/92

B. LICENSE FEE MANAGEMENT BRANCH (CHECK WHEN MILESTONE 03 IS ENTERED /_✓)

1. FEE CATEGORY AND AMOUNT: 3C #490

2. CORRECT FEE PAID. APPLICATION MAY BE PROCESSED FOR:
AMENDMENT ✓
RENEWAL
LICENSE

3. OTHER

SIGNED A Crutchfield
DATE 12-14-92

Roanoke
Memorial
Hospitals

Office of the
Vice President

November 19, 1992

An Affiliate of CARILION *Health System*

Nuclear Regulatory Commission
Region II
101 Marietta Street
Atlanta, GA 30303

Ref: 10 CFR 35.13 (e)

Subject: Amendment to Radioactive Material License #45-01291-04MD

Gentlemen:

Roanoke Memorial Hospitals is requesting amendment to Radioactive Material License #45-01291-04MD for the following purpose: We intend to relocate the Nuclear Pharmacy Services facility from its present site on the 3rd Floor of the main hospital complex (Item 9.1 of our renewal application, dated 3/14/88, citing Item 11-original application dated 11/29/82) at Belleview and Jefferson Streets, to a 4th Floor area at the same address (Attachment A), in order to gain additional needed work space. The proposed area is not located on an existing patient floor. The floor area below this site is presently assigned as office space in the main Medical Laboratory Department and the floor above is an operating room in the Surgery Department.

The existing Radiopharmacy area will be redesignated to an unrestricted area. Once vacated, the existing area will be surveyed for radioactive contamination, and if necessary, appropriately decontaminated to assure radiation levels are equal to or less than the unrestricted area limits as per 10 CFR 20. All existing radiation safety procedures will be followed as per our present license during and after the relocation.

An amendment fee of $490.00 has been enclosed to initiate review of this request. We remain available to provide additional information and appreciate your prompt attention to this request.

Sincerely,

Stephen A. Purves
Vice President

Attachment
cc: Radiation Safety Committee

Log Dec 4 II
Remitter Carilion Svcs, Inc.
Check No. 343300
Amount $490
Fee Category 3C
Type of Fee Amendment
Date Check Rec'd Dec 14, 1992
Date Completed Dec 15, 1992
By: DAC

Nuclear Pharmacy Services, 4th Floor, Main Hospital Complex
Roanoke Memorial Hospital, Belleview @ Jefferson Sts., Roanoke, VA



(Note previously Room Suite 420-west)